Duke Debates Controversies in the Management of Hematologic Malignancies

Asheville, NC US
April 21, 2017 to April 23, 2017

The purpose of this conference is to educate oncologists, hematologists, and the healthcare team regard- ing evolving and contemporary standards of care for the optimal treatments of patients with hematologic malignancies. Practical issues, current standards, and controversies in the management of these diseases will be discussed in debates, traditional lecture and tumor board.

Learning Objectives

  1. Discuss management strategies for side effect management of targeted therapy treatments 
  2. Discuss new avenues for the use of stem cell therapy and hematopathology. 
  3. Discuss the role of immunotherapy in managing patients with hematologic malignancies 
  4. Discuss emerging data and recent advances in the treatment of patients with Leukemia, Lymphoma, and Benign Hematologic disorders
  5. Discuss treatment strategies for patients with CML and PMF
Course summary
Available credit: 
  • 12.50 ACPE
  • 12.50 AMA PRA Category 1 Credit(s)
  • 12.50 ANCC
  • 12.50 Attendance
Registration Opens: 
Registration Expires: 
Activity Starts: 
04/21/2017 - 3:00pm
Activity Ends: 
04/23/2017 - 11:00am
Grove Park Inn
290 Macon Ave.
Asheville, NC 28804
United States

Donna Adams, MSN, ANP-BC, OCN
Christopher Kelsey, MD
Anand Lagoo, MD, PhD
Matthew McKinney, MD
Ara Metjian, MD
Meredith Moorman, PharmD, CPP
Lindsay Rein, MD
Keith Sullivan, MD
Anthony Sung, MD
Linda Sutton, MD
Marilyn Telen, MD
Anjali Advani, MD
Anne Beaven, MD
Danielle Brander, MD
Louis Diehl, MD
Harry Erba, MD
Michel Khouri, MD
Anthony Mato, MD
Chad McCall, MD, PhD
Joseph Moore, MD
Craig Moskowitz, MD
Heather Paradis, MSN, ANP
David Porter, MD
David Rizzieri, MD
Brady Stein, MD
Richard Stone, MD
John Strouse, MD


Available Credit

  • 12.50 ACPE
  • 12.50 AMA PRA Category 1 Credit(s)
  • 12.50 ANCC
  • 12.50 Attendance

Accreditation Period

Registration Opens: 
Registration Expires: 


Please login or register to take this course.